基因组衍生肿瘤类型预测辅助临床癌症诊疗
该研究开发了一种机器学习方法,利用常规临床靶向DNA测序数据(包括离散分子改变和推断特征如突变特征)预测肿瘤类型。该方法在血浆游离DNA和原发灶不明癌症中也有较好预测能力,并前瞻性应用使2例初诊为转移性乳腺癌的患者获得基因组导向的诊断再评估和更合适的治疗。
要点
- 基于靶向测序的机器学习模型可预测肿瘤类型,训练集准确率73.8%,独立队列74.1%。
- 高置信度预测(>95%概率)占3388例(43.5%)。
- 血浆cfDNA预测准确率75.0%(45/60),原发灶不明癌症预测率67.4%(95/141)。
核心结论
- 将人工智能应用于肿瘤起源预测可作为传统组织学检查的有用补充,提供整合病理诊断并常具重要治疗意义。
研究设计与样本
- 研究开发机器学习方法,基于靶向 panel DNA 序列数据预测肿瘤类型,训练集为7791例晚期癌症患者的前瞻性测序队列,涵盖22种癌症类型。
主要发现
- 3388例(43.5%)预测概率>95%,为高置信度预测。
- 血浆游离DNA分析在60例中45例(75.0%)获得准确预测。
- 原发灶不明癌症患者中,141例中95例(67.4%)通过靶向肿瘤测序预测出可能的组织起源。
- 前瞻性应用于2例初诊为转移性乳腺癌的患者,基因组导向的诊断再评估引导选择更合适的治疗并取得临床反应。
临床怎么用
- 基因组衍生的肿瘤类型预测可辅助传统组织学审查,提供整合病理诊断,尤其在诊断不明确或原发灶不明时。
- 高置信度预测(>95%概率)可指导治疗决策,但需结合临床和病理综合判断。
- 血浆cfDNA测序可能作为癌症筛查的辅助手段,用于预测肿瘤类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Diagnosing the site of origin for cancer is a pillar of disease classification that has directed clinical care for more than a century. Even in an era of precision oncologic practice, in which treatment is increasingly informed by the presence or absence of mutant genes responsible for cancer growth and progression, tumor origin remains a critical factor in tumor biologic characteristics and therapeutic sensitivity. OBJECTIVE: To evaluate whether data derived from routine clinical DNA sequencing of tumors could complement conventional approaches to enable improved diagnostic accuracy. DESIGN, SETTING, AND PARTICIPANTS: A machine learning approach was developed to predict tumor type from targeted panel DNA sequence data obtained at the point of care, incorporating both discrete molecular alterations and inferred features such as mutational signatures. This algorithm was trained on 7791 tumors representing 22 cancer types selected from a prospectively sequenced cohort of patients with advanced cancer. RESULTS: The correct tumor type was predicted for 5748 of the 7791 patients (73.8%) in the training set as well as 8623 of 11 644 patients (74.1%) in an independent cohort. Predictions were assigned probabilities that reflected empirical accuracy, with 3388 cases (43.5%) representing high-confidence predictions (>95% probability). Informative molecular features and feature categories varied widely by tumor type. Genomic analysis of plasma cell-free DNA yielded accurate predictions in 45 of 60 cases (75.0%), suggesting that this approach may be applied in diverse clinical settings including as an adjunct to cancer screening. Likely tissues of origin were predicted from targeted tumor sequencing in 95 of 141 patients (67.4%) with cancers of unknown primary site. Applying this method prospectively to patients under active care enabled genome-directed reassessment of diagnosis in 2 patients initially presumed to have metastatic breast cancer, leading to the selection of more appropriate treatments, which elicited clinical responses. CONCLUSIONS AND RELEVANCE: These results suggest that the application of artificial intelligence to predict tissue of origin in oncologic practice can act as a useful complement to conventional histologic review to provide integrated pathologic diagnoses, often with important therapeutic implications.
引用
- Penson A, Camacho N, Zheng Y, et al. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncol. 2020. PMID: 31725847. doi:10.1001/jamaoncol.2019.3985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。